TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00605826

Intervention type: DEVICE
Group type: OTHER
Intervention: NASHA/Dx (Solesta) Gel
Description: Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NASHA/Dx (Solesta) Gel
Description: Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Injection
Description: Sham injection at the start of the blinded phase.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection at the start of the blinded phase.
Study: NCT01706913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermatology consult
Study: NCT02000843

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tympanoplasty -- conchal cavum approach
Description: Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
Study: NCT03214835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo CDx Brush biopsy
Description: In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo CDx Brush biopsy
Description: In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
Study: NCT00562419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-322
Description: IV solution, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-322
Description: IV solution, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV solution, biweekly
Study: NCT01175512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Study: NCT01172080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol of reminders regarding due colonoscopy
Description: Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
Study: NCT03386708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intrauterine injection
Description: intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell
Description: 2 \* 10\^7 cells (2ml)
Study: NCT02365428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity text messages
Study: NCT01104220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
Study: NCT01530490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline and Hydroxyethyl Starch
Description: 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Description: 0.5 mg cabergoline administration 8 days
Study: NCT00296322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, mitomycin-C, doxifluridine
Description: Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, mitomycin-C, doxifluridine
Description: Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
Study: NCT02793284

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT scan
Description: PET/CT scan using the radioactive agent 18F-DCFPyL
Study: NCT00684814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg tablet
Description: 10 mg tablet administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg tablet (Ambien®)
Description: 10 mg tablet administered after an overnight fast of at least 10 hours
Study: NCT00643149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: 10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: 60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
Study: NCT04519554

Intervention type: DEVICE
Group type: OTHER
Intervention: Endometrial sampling
Description: Endometrial sampling with 2 different forceps

Intervention type: DEVICE
Group type: OTHER
Intervention: Endometrial sampling
Description: Endometrial sampling with 2 different forceps
Study: NCT03596164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial Adapter for Device
Description: Vial adapter for device is approved for use in Japan by PMDA.
Study: NCT02635230

Intervention type: DRUG
Intervention: Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
Study: NCT04227691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed Nd Yag laser treatment
Description: One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPL treatment
Description: One treatment of the assigned axilla with IPL treatment in ten patients
Study: NCT01676961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: romiplostim
Description: Given SC
Study: NCT04073745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT03929419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: application of 160 units human insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: nasal spray containing placebo solution
Study: NCT01398436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: central venous catheter positioning in right atrium
Description: A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
Study: NCT01951066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Implant
Description: Patients will receive a single injection of a dexmethasone implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Implant
Description: Patients will receive a single injection of a dexmethasone implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF injection
Description: Patients will receive PRN injections of an anti-VEGF agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF injection
Description: Patients will receive PRN injections of an anti-VEGF agent
Study: NCT00679198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-patient communication
Description: We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting.
Study: NCT04608864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: varicocelectomy
Description: microsurgical subinguinal varicocelectomy
Study: NCT01198158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03377088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rose oil
Description: Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
Study: NCT04012255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide (administered by PDS290 pen)
Description: Increasing doses of semaglutide given sc in the stomach for 21 weeks
Study: NCT00597649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicifadine
Description: SR dosage form of 400 mg bid or tid for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicifadine
Description: SR dosage form of 400 mg bid or tid for one year
Study: NCT03377088

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Almond Oil
Description: Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
Study: NCT02316613

Intervention type: DRUG
Intervention: Rituximab
Study: NCT02782468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 25 mg/m^2
Description: Pevonedistat 25 mg/m\^2 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 44 mg/m^2
Description: Pevonedistat 44 mg/m\^2 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 10 mg/m^2
Description: Pevonedistat 10 mg/m\^2 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 20 mg/m^2
Description: Pevonedistat 20 mg/m\^2 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m^2
Description: Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
Study: NCT03864965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning
Description: The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
Study: NCT02782468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m^2
Description: Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
Study: NCT03818568

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketoanalogues of essential amino acids
Description: Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketoanalogues of essential amino acids
Description: Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
Study: NCT03805139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ajwa Date (phoenix dactylifera)
Description: Effect of Ajwa on Dyslipidemia
Study: NCT02979288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus (Lcr 35 regenerans)
Description: Probiotic vaginal tablets vith active probiotic strains

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus (Lcr 35 regenerans)
Description: Probiotic vaginal tablets vith active probiotic strains

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO Intervention
Description: NO Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO Intervention
Description: NO Intervention
Study: NCT03915379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67571244
Description: JNJ-67571244 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67571244
Description: JNJ-67571244 will be administered.
Study: NCT03928327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin Capsules
Study: NCT00785629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03047681

Intervention type: DIAGNOSTIC_TEST
Intervention: venous blood withdrawl
Description: patients will be asked for a venous blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: venous blood withdrawl
Description: patients will be asked for a venous blood sample
Study: NCT02142010

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel liposome injection plus cisplatin
Description: Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
Study: NCT04179890

Intervention type: DRUG
Intervention: Afatinib (Gi(l)otrif®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

Intervention type: DRUG
Intervention: Erlotinib (Tarceva®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

Intervention type: DRUG
Intervention: Gefitinib (IRESSA®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

Intervention type: DRUG
Intervention: Osimertinib (Tagrisso®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Study: NCT04273724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Interventions for Impairments Identified During Geriatric Assessment
Description: Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
Study: NCT03574207

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
Study: NCT04179890

Intervention type: DRUG
Intervention: Afatinib (Gi(l)otrif®)
Description: As first line therapy.

Intervention type: DRUG
Intervention: Osimertinib (Tagrisso®)
Description: In the case the T790M resistance mutation was developed (second line therapy).
Study: NCT01748227

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer-Delivered Pain Self-Management
Description: Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
Study: NCT02460003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A program of physiotherapy including manual therapy, exercise, pain education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home exercise program
Study: NCT03664739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: IDP-120 Gel, once-daily application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDp-120 Vehicle Gel
Description: IDP-120 Vehicle Gel, once-daily application
Study: NCT01770249

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Per-oral Endoscopic Esophagomyotomy (POEM)
Description: The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
Study: NCT02922673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT05368870

Intervention type: PROCEDURE
Intervention: Carlevale implantation
Description: Vitrectomy and Carlevale implantation
Study: NCT04254887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EPBD
Description: Small incision of the duodenal nipple + EPBD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EST
Description: Large incision of the duodenal nipple + EPBD
Study: NCT00095238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
Study: NCT02632903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT01437995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol Diskus
Description: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol Diskus
Description: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Diskus
Description: Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Study: NCT02457273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC 388
Description: 40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
Study: NCT00872027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills for 8 weeks
Study: NCT02922673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01667848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optitherm® device activated
Description: The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optitherm® device inactivated
Description: The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
Study: NCT01660815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: IV injection, 370 MBq (10mCi), single dose